{"entity":{"id":"nct06986811","kind":"trial","name":"CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours","aka":[],"tldr":"A phase 2 trial of Standard surgery in childhood cancers, run by CEBIOTEX, now recruiting.","summary":"CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours is a phase 2 interventional study registered as NCT06986811 by CEBIOTEX, with 60 participants planned, started 2025-05-06 and due to reach its primary completion in 2029-05. Interventions recorded: Standard surgery and CEB-01.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06986811","url":"https://clinicaltrials.gov/study/NCT06986811"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cebiotex"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06986811","phase":"2","setting":"First-in-paediatrics, Open Label, Exploratory, Externally Controlled Clinical Trial to Evaluate Safety, Efficacy and Pharmacokinetics of 7-ethyl-10-hydroxy Camptothecin (SN-38) Formulated as a Biocompatible Polymeric Nanofiber Membrane (CEB-01) for Treatment, in Addition to Standard of Care, of Paediatric Patients From Birth to Less Than 18 Years of Age With a Locally Resectable Tumours in Comparison to Standard of Care","sponsor":"CEBIOTEX","enrolled":60,"outcomes":[]},"route":"/trials/nct06986811/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"}],"company":[{"id":"cebiotex","kind":"company","name":"CEBIOTEX","route":"/companies/cebiotex/"}]}}